UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and in combination with ipilimumab in malignant melanoma. This study will explore the safety, tolerability and efficacy of UV1 administered with GM-CSF in melanoma patients who are also receiving pembrolizumab.
Malignant Melanoma
DRUG: UV1|DRUG: GM-CSF
Number of patients with treatment-related adverse events, Frequency and severity of adverse events, Up to week 29
Tumor response, RECIST and iRECIST, Up to week 52|The length of time from the start of treatment that patients are still alive., Overall survival, up to 2 years
UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and in combination with ipilimumab in malignant melanoma. This study will explore the safety, tolerability and efficacy of UV1 administered with GM-CSF in melanoma patients who are also receiving pembrolizumab.